5 results
Primary Objective- To evaluate the clinical efficacy and safety of oral apremilast (APR) 30 mg twice a day (BID) compared with placebo, in subjects with moderate to severe plaque psoriasis at Week 16.Secondary Objectives- To evaluate the clinical…
Primary ObjectiveTo evaluate the clinical efficacy of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in subjects with active UC.Secondary Objective To evaluate the safety and tolerability of apremilast (30 mg BID and 40…
Primary Objective:To evaluate the long-term safety and tolerability of eptinezumab in patients with chronic cluster headache (cCH)Secondary ObjectivesTo evaluate the efficacy of eptinezumab in patients with cCHExploratory ObjectiveTo explore the…
Primary Objective:- To evaluate the efficacy of eptinezumab in patients with eCHSecondary Objectives:- To evaluate the efficacy of eptinezumab on health-related quality of life, health care resource utilization, and work productivitySafety…
Phase 1• To determine the maximum tolerated dose (MTD) and RP2D of BLU 945 as monotherapy and in combination with osimertinib• To determine the safety and tolerability of BLU 945 as monotherapy and in combination with osimertinibPhase 2• To assess…